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Regulating Nanomedicine: A European perspective 
 
Abstract 
The potential impact of nanomedicine is foreseen to radically change health care; however it also 
challenges existing perceptions, dynamics and standards relating to ethics, safety and 
governance. This commentary briefly highlights aspects and approaches pertaining to 
nanomedical regulation in the European Union. 
 
Current approach to nanomedical regulation 
As with many applications in the nano area,1 there is no specific nanomedical legislation in the 
European Union; however this does not mean that it is unregulated. Legislation on medicinal 
products and devices, tissue engineering and other advanced therapies are applicable to 
nanomedicine. These legislations are based on established legal principles pertaining to 
pharmaceuticals, medical products, devices and other biomedical issues. 
 
Despite calls for the drafting and introduction of new nanomedical regulation, legislators in the 
European Union have taken the approach that it is best to continue to regulate nanomedical 
products and devices under the existing regulatory directives, wherever possible rather than 
create a completely new regulatory regime for nanomedicine. This would seem to be a logical 
step in the short term as the regime for medical products and devices regulation in Europe is 
relatively elaborate. However in the long term none of these regulations or directives were 
written with nanomedicinal applications in mind, and will need to be revised accordingly to take 
into account specific risks and challenges posed by nanomedicine2. This revisionary or 
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incremental approach seems to be the one European legislators are willing to take.3 In its opinion 
to the European Commission, the European Group on Ethics in Science and New Technologies 
(EGE)4 states that there is extensive regulation of areas where nanomedicine is used in products 
and hence new nano-specific regulatory structures are not required at this point, the focus should 
however be on the proper implementation of already existing regulations. A similar opinion can 
be seen in the report by the Commission’s New and Emerging Technologies Working Group 
(N&ET)5 and the European Commission’s ‘communication on regulatory aspects of 
nanomaterials’6, which conclude that in principle existing medical legislation is suitable to deal 
with products and devices manufactured or utilising nanotechnology though on a note of caution 
given the uncertainties pertaining to nanoparticles such as novel properties, hazard evaluation, 
exposure evaluation and overall risk assessment, current procedures are likely to require 
modification. 
 
Regulatory uncertainty and related concerns 
The use of existing regulations and standards to regulate nanomedicine is fraught with concerns 
and difficulties7. With the advancement of nanomedicine the borderline between medicines, 
devices and therapies is becoming increasingly blurred and this is also likely to cause the blurring 
of traditional boundaries between different regulatory and classification systems. While various 
European Union directives on medical products8 and medical devices9 lay down essential 
requirements that have to be fulfilled before any medicinal product or device is place on the 
                                                 
3  The Scientific Committee on Emerging and Newly Identified Health Risks (SCHENIR) (2007), The 
appropriateness of the risk assessment methodology in accordance with the Technical Guidance Documents for new 
and existing  substances for assessing the risks of nanomaterials; 
<http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf>. 
4 EGE (2007), Opinion 21 - On the ethical aspects of nanomedicine, Retrieved 15 March 2008 
<http://ec.europa.eu/european_group_ethics/publications/docs/final_publication_%20op21_en.pdf> 
5 N&ET Working Group (2007), Report on nanotechnology to the medical devices expert group findings and 
recommendations, p.5 <http://ec.europa.eu/enterprise/medical_devices/net/entr-2007-net-wg-report-nano-final.pdf> 
Retrieved on 5 April 2008.  
6 Regulatory aspects of nanomaterials, COM 366 (2008) p.11. Retrieved 2 July 2008.  < 
http://www.euractiv.com/29/images/SEC(2008)%202036_tcm29-173474.pdf > 
7  See, Editorial - Regulating nanomedicine, Nature Materials 6 (2007), p 249. 
8 Such as Directive 2001/83/EC on Medicinal products for human use. 
9 Medical devices are regulated by Directive 93/42/EEC (The Medical Devices Directive); Directive 90/385/EEC 
(The Active Implantable Medical Devices Directive); and Directive 98/79/EC (The In Vitro Diagnostic Medical 
Devices Directive). 
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market, these are general and non-specific. The risk assessment, safety and quality requirements 
are to be fulfilled by conformity to established quality systems and published product standards 
that may not be suitably designed to address various aspects relating to nanomedicine. As 
progress in medicine and nanoscience accelerates in the manufacture and characterisation of 
nanoscale materials and nano-enabled products, it will become increasingly important to 
researchers, manufacturers, regulators and other stake holders to have agreed upon 
nanotechnology standards10. Steps have been initiated for example in the case of the CEN/TC 
352 to establish nano-standards whose effectiveness and adequacy, however are yet to be 
ascertained. These standards will have to address the evaluation of the quality, safety, efficacy 
and risk-management of nanomedicinal products. Whether such standards if introduced by the 
EU are likely to be broad guidelines or legally binding requirements however is not clear. There 
is divided opinion on this as highlighted by the EU Directorate General Enterprise and Industry’s 
consultation on proposals to amend Directive 2001/83/EC11 as regards advanced therapy 
medicinal products where a majority of the stakeholders expressed the opinion that Annex I 
which only lays down ‘essential requirements’ should be supplemented by flexible guidelines 
and not by strict legally binding rules as doing so is seen as likely to impair the development of 
novel medical products12. 
A major concern is also insufficient knowledge and scientific data concerning nanoparticle 
characterisation, their detection and measurement, the persistence of nanoparticles in humans and 
in the environment, as well as toxicology related to nanoparticles. Unless further toxicological 
and risk studies are performed and guidelines introduced many nanomedicinal products are likely 
to pose short term and long term risks to health and the environment. Though modification of 
existing regulations and standards to incorporate nanomedicine seems to be the likely recourse, it 
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will not address the more fundamental issue – that existing risk assessment methodologies may 
be inadequate primarily due to their reliance on mass metrics.13 While the small size of particles 
makes them so useful in medical applications, it is also one of the main concerns. There are also 
many types of nanoparticles and nanomaterials and one of the challenges is to be able to 
categorise and prioritise these for the purpose of risk assessment. Hence if existing regulations 
are modified to make them more nano-conversant, existing risk methodologies will also have to 
be adapted to introduce agglomeration, particle size, shape and surface reactivity into the 
assessment criteria.14 
Concluding remarks 
While nanomedicine provides great promise and a future of revolutionary applications seems to 
beckon, it also introduces several new regulatory challenges. Regulatory bodies and legislators in 
the European Union have so far approached nanomedicine regulation with caution and have 
refrained from drastic measures or changes. As nanomedicine evolves and more products and 
devices are introduced it will become clear if this incremental approach is appropriate or more 
specific nanomedicine regulation need be introduced. Regulatory approaches based on co-
regulation, self-regulation and voluntary codes of conducts may also have to be developed so as 
to widen the regulatory matrix. The direction and application of nanomedicine in the long term 
will depend on how these current challenges are addressed.  
                                                 
13 SCHENIR opinion (2007). 
14  See, Richard D. Handy, Richard Owen, Eugenia Valsami Jones (2008), The ecotoxicology of nanoparticles and 
nanomaterials: current status, knowledge gaps, challenges and future needs, Ecotoxicology 17, pp.315-325.        
